1-3 of 3
Hong Ren
Close
Sort by
Journal Articles

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas

Clinical Trials & Observations Brief Report
Michelle A. Fanale, Steven M. Horwitz, Andres Forero-Torres, Nancy L. Bartlett, Ranjana H. Advani, Barbara Pro, Robert W. Chen, Andrew Davies, Tim Illidge, Mayur Uttarwar, Shih-Yuan Lee, Hong Ren, Dana A. Kennedy, Andrei R. Shustov
Journal: Blood
Blood (2018) 131 (19): 2120–2124.
https://doi.org/10.1182/blood-2017-12-821009
Published: 2018
Includes: Supplemental data
Journal Articles

Five-Year Survival Results: Frontline Brentuximab Vedotin in Combination with CHP in Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Michelle A. Fanale, MD, Steven M. Horwitz, MD, Andres Forero-Torres, MD, Nancy L. Bartlett, MD, Ranjana H. Advani, MD, Barbara Pro, MD, Robert W. Chen, MD, Andrew Davies, PhD, Tim M. Illidge, MDPhD, Mayur Uttarwar, Dirk Huebner, MD, Hong Ren, MD, Andrei R. Shustov, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2790.
https://doi.org/10.1182/blood.V130.Suppl_1.2790.2790
Published: 2017
Journal Articles

Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Michelle A Fanale, MD, Steven M Horwitz, MD, Andres Forero-Torres, MD, Nancy L Bartlett, MD, Ranjana H Advani, MD, Barbara Pro, MD, Robert W Chen, MD, Andrew J Davies, FRCP PhD, Tim Illidge, PhD, Mayur Uttarwar, Dirk Huebner, MD, Hong Ren, MD, Andrei R Shustov, MD
Journal: Blood
Blood (2016) 128 (22): 2993.
https://doi.org/10.1182/blood.V128.22.2993.2993
Published: 2016